Merck: FDA to Review Doravirine/Islatravir Regimen in HIV-1 Infection

 Merck & Co. said the U.S. Food and Drug Administration will review its application seeking approval of its proposed doravirine/islatravir regimen in certain adults with HIV-1 infection.

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy.

The Rahway, N.J., drugmaker said the FDA has set a target action date of April 28, 2026, for the application.

https://www.morningstar.com/news/dow-jones/202507103543/merck-fda-to-review-doravirineislatravir-regimen-in-hiv-1-infection